Exact Mass: 395.13688060000004

Exact Mass Matches: 395.13688060000004

Found 55 metabolites which its exact mass value is equals to given mass value 395.13688060000004, within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error 0.001 dalton.

Novobiocic acid

Novobiocic acid

C22H21NO6 (395.13688060000004)


A hydroxycoumarin that is the aglycone of novobiocin.

   

Morniflumate

2-(morpholin-4-yl)ethyl 2-{[3-(trifluoromethyl)phenyl]amino}pyridine-3-carboxylate

C19H20F3N3O3 (395.1456686)


M - Musculo-skeletal system > M01 - Antiinflammatory and antirheumatic products > M01A - Antiinflammatory and antirheumatic products, non-steroids C254 - Anti-Infective Agent > C28394 - Topical Anti-Infective Agent

   

Benzomalvin C

(2S,3S)-6-Methyl-3-phenyl-13H-spiro[oxirane-2,7-quinazolino[3,2-a][1,4]benzodiazepine]-5,13(6H)-dione

C24H17N3O3 (395.12698520000004)


   
   

7-hydroxy-1-(1-hydroxyethyl)-8-methyl-2,3,8,9a,10,12a-hexahydro-6H-benzo[cd]furo[2,3:5,6]pyrano[3,4-g]pyrrolo[1,2-a]indole-6,11(1H)-dione

7-hydroxy-1-(1-hydroxyethyl)-8-methyl-2,3,8,9a,10,12a-hexahydro-6H-benzo[cd]furo[2,3:5,6]pyrano[3,4-g]pyrrolo[1,2-a]indole-6,11(1H)-dione

C22H21NO6 (395.13688060000004)


   
   
   

3-Methyl-3-(6,7-dimethoxyisoquinoline-1-yl)-4,7-dimethoxyisobenzofuran-1(3H)-one

3-Methyl-3-(6,7-dimethoxyisoquinoline-1-yl)-4,7-dimethoxyisobenzofuran-1(3H)-one

C22H21NO6 (395.13688060000004)


   
   
   
   
   
   

3-(6,7-Dimethoxy-isoquinolin-1-yl)-3-(3,4-dimethoxy-phenyl)-acrylic acid

"NCGC00160257-01!3-(6,7-Dimethoxy-isoquinolin-1-yl)-3-(3,4-dimethoxy-phenyl)-acrylic acid"

C22H21NO6 (395.13688060000004)


   
   

C24H17N3O3_Spiro[oxirane-2,7(13H)-quinazolino[3,2-a][1,4]benzodiazepine]-5,13(6H)-dione, 6-methyl-3-phenyl-, (2S,3S)

NCGC00180312-03_C24H17N3O3_Spiro[oxirane-2,7(13H)-quinazolino[3,2-a][1,4]benzodiazepine]-5,13(6H)-dione, 6-methyl-3-phenyl-, (2S,3S)-

C24H17N3O3 (395.12698520000004)


   

(2S,3S)-6-methyl-3-phenylspiro[oxirane-2,7-quinazolino[3,2-a][1,4]benzodiazepine]-5,13-dione

(2S,3S)-6-methyl-3-phenylspiro[oxirane-2,7-quinazolino[3,2-a][1,4]benzodiazepine]-5,13-dione

C24H17N3O3 (395.12698520000004)


   
   

N-(4,7-Dihydroxy-8-methyl-2-oxo-2H-chromen-3-yl)-2,2-dimethylchromane-6-carboxamide

N-(4,7-Dihydroxy-8-methyl-2-oxo-2H-chromen-3-yl)-2,2-dimethylchromane-6-carboxamide

C22H21NO6 (395.13688060000004)


   

[4-(2,4-difluorophenyl)-2-[(2,5-dimethylphenyl)carbamoyl]phenyl] acetate

[4-(2,4-difluorophenyl)-2-[(2,5-dimethylphenyl)carbamoyl]phenyl] acetate

C23H19F2NO3 (395.13329280000005)


   
   

Grepafloxacin hydrochloride

Grepafloxacin hydrochloride

C19H23ClFN3O3 (395.14118900000005)


D000970 - Antineoplastic Agents > D059003 - Topoisomerase Inhibitors > D059005 - Topoisomerase II Inhibitors D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D024841 - Fluoroquinolones C254 - Anti-Infective Agent > C258 - Antibiotic > C795 - Quinolone Antibiotic D004791 - Enzyme Inhibitors

   
   

Orbifloxacin

Orbifloxacin

C19H20F3N3O3 (395.1456686)


D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D024841 - Fluoroquinolones C254 - Anti-Infective Agent > C258 - Antibiotic > C795 - Quinolone Antibiotic

   

[4-(2,4-difluorophenyl)-2-(propylcarbamoyl)phenyl] benzoate

[4-(2,4-difluorophenyl)-2-(propylcarbamoyl)phenyl] benzoate

C23H19F2NO3 (395.13329280000005)


   
   

(2E)-2-Methyl-4-(9H-purin-6-ylamino)-2-buten-1-yl beta-D-glucopyranosiduronic acid

(2E)-2-Methyl-4-(9H-purin-6-ylamino)-2-buten-1-yl beta-D-glucopyranosiduronic acid

C16H21N5O7 (395.1440916)


   

N-(4,6-dimethyl-2-pyridinyl)-4-[5-(trifluoromethyl)-2-pyridinyl]-1-piperazinecarbothioamide

N-(4,6-dimethyl-2-pyridinyl)-4-[5-(trifluoromethyl)-2-pyridinyl]-1-piperazinecarbothioamide

C18H20F3N5S (395.13914360000007)


   

Morniflumate

Morniflumate

C19H20F3N3O3 (395.1456686)


M - Musculo-skeletal system > M01 - Antiinflammatory and antirheumatic products > M01A - Antiinflammatory and antirheumatic products, non-steroids C254 - Anti-Infective Agent > C28394 - Topical Anti-Infective Agent

   

beta-L-arabinofuranosyl-(1->2)-beta-L-arabinofuranosyl-hydroxyproline

beta-L-arabinofuranosyl-(1->2)-beta-L-arabinofuranosyl-hydroxyproline

C15H25NO11 (395.14275399999997)


   

(4S)-4-[(2S,3R,4S,5S)-3-[(2R,3R,4R,5S)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]oxypyrrolidine-2-carboxylic acid

(4S)-4-[(2S,3R,4S,5S)-3-[(2R,3R,4R,5S)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]oxypyrrolidine-2-carboxylic acid

C15H25NO11 (395.14275399999997)


   

5-(4-chlorophenyl)-N-[4-(4-methyl-1-piperazinyl)phenyl]-2-furancarboxamide

5-(4-chlorophenyl)-N-[4-(4-methyl-1-piperazinyl)phenyl]-2-furancarboxamide

C22H22ClN3O2 (395.14004620000003)


   
   
   

2-(3,4-Dimethoxyphenyl)-9-(4-fluorophenyl)-2,3-dihydropurine-6-carboxamide

2-(3,4-Dimethoxyphenyl)-9-(4-fluorophenyl)-2,3-dihydropurine-6-carboxamide

C20H18FN5O3 (395.139361)


   

2-(2-methoxyethyl)-9-methyl-1-oxo-N-(thiophen-2-ylmethyl)-4-pyrido[3,4-b]indolecarboxamide

2-(2-methoxyethyl)-9-methyl-1-oxo-N-(thiophen-2-ylmethyl)-4-pyrido[3,4-b]indolecarboxamide

C21H21N3O3S (395.13035560000003)


   

N-[3-(3-chlorophenyl)phenyl]-1-(3-isoxazolylmethyl)-4-piperidinecarboxamide

N-[3-(3-chlorophenyl)phenyl]-1-(3-isoxazolylmethyl)-4-piperidinecarboxamide

C22H22ClN3O2 (395.14004620000003)


   
   
   

(E)-3-(6,7-dimethoxyisoquinolin-1-yl)-3-(3,4-dimethoxyphenyl)prop-2-enoic acid

(E)-3-(6,7-dimethoxyisoquinolin-1-yl)-3-(3,4-dimethoxyphenyl)prop-2-enoic acid

C22H21NO6 (395.13688060000004)


   

2-Me-alpha-D-Fucp4NAc-(1->4)-beta-D-GlcpA

2-Me-alpha-D-Fucp4NAc-(1->4)-beta-D-GlcpA

C15H25NO11 (395.14275399999997)


An amino disaccharide consisting of beta-D-glucopyranuronic acid having a 4-acetamido-4,6-dideoxy-2-O-methyl-alpha-L-galactopyranosyl attached at the 4-position.

   

BE-54238B

BE-54238B

C22H21NO6 (395.13688060000004)


An organic heterohexacyclic compound that is isolated from Streptomyces sp. A54238. It exhibits inhibitory efficacy against the growth of human tumour cells.

   

FASN-IN-1

FASN-IN-1

C18H25N3O3S2 (395.13372599999997)


FASN-IN-1 is a fatty acid synthase (FASN) inhibitor extracted from patent WO2015134790A1, compound 56[1].

   

(2s,3r)-9'-methyl-3-phenyl-1',9',12'-triazaspiro[oxirane-2,10'-tetracyclo[9.8.0.0²,⁷.0¹³,¹⁸]nonadecane]-2',4',6',11',13',15',17'-heptaene-8',19'-dione

(2s,3r)-9'-methyl-3-phenyl-1',9',12'-triazaspiro[oxirane-2,10'-tetracyclo[9.8.0.0²,⁷.0¹³,¹⁸]nonadecane]-2',4',6',11',13',15',17'-heptaene-8',19'-dione

C24H17N3O3 (395.12698520000004)


   

11-hydroxy-20-(1-hydroxyethyl)-9-methyl-4,8-dioxa-21-azahexacyclo[10.9.1.0²,¹⁰.0³,⁷.0¹⁶,²².0¹⁷,²¹]docosa-1,10,12(22),14,16-pentaene-5,13-dione

11-hydroxy-20-(1-hydroxyethyl)-9-methyl-4,8-dioxa-21-azahexacyclo[10.9.1.0²,¹⁰.0³,⁷.0¹⁶,²².0¹⁷,²¹]docosa-1,10,12(22),14,16-pentaene-5,13-dione

C22H21NO6 (395.13688060000004)


   

12-[2-(dimethylamino)ethyl]-13,14-dimethoxy-3,5,16-trioxapentacyclo[9.6.2.0²,⁶.0⁸,¹⁸.0¹⁵,¹⁹]nonadeca-1,6,8(18),9,11(19),12,14-heptaen-17-one

12-[2-(dimethylamino)ethyl]-13,14-dimethoxy-3,5,16-trioxapentacyclo[9.6.2.0²,⁶.0⁸,¹⁸.0¹⁵,¹⁹]nonadeca-1,6,8(18),9,11(19),12,14-heptaen-17-one

C22H21NO6 (395.13688060000004)